AstraZeneca’s Imfinzi Fails Phase III NSCLC Trial, Aces Late-Stage Bladder Cancer Study

AstraZeneca HQ, CA/iStock, Sundry Photography

Pictured: AstraZeneca’s headquarters in Silicon Valley/iStock, Sundry Photography

AstraZeneca announced Tuesday that its PD-L1 inhibitor Imfinzi (durvalumab) did not meet its primary endpoint in the Phase III ADJUVANT BR.31 study in early stage non-small cell lung cancer.

Without revealing specific data, AstraZeneca said that Imfinzi was unable to significantly improve disease-free survival versus placebo in patients with stage IB to IIIA non-small cell lung cancer (NSCLC) following complete tumor resection. The pharma noted that it will share data from ADJUVANT BR.31 at a future scientific meeting.

Susan Galbraith, executive vice president of oncology R&D at AstraZeneca, in a statement said that the pharma is “disappointed” by these results. Nevertheless, Imfinzi has established itself as an important cancer therapy and has “helped change the treatment landscape” in lung cancer, with several positive late-stage findings in patients in the earlier stages…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks